Mukharram M. Bikbov

Dr. Mukharram M. Bikbov

orcid

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2017 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TATin Aung
Tin Aung
MOMineo Ozaki
Mineo Ozaki
MLMei Chin Lee
Mei Chin Lee
USUrsula Schlötzer-Schrehardt
Ursula Schlötzer-Schrehardt
GTGudmar Thorleifsson
Gudmar Thorleifsson
CKChiea Chuen Khor
Chiea Chuen Khor

15 July 2013 in Acta Ophthalmologica
Verified
Journal Article
Open access
PDF file
GBGuzel Bikbova
Guzel Bikbova
MBMukharram M. Bikbov
Mukharram M. Bikbov
: Purpose:  To evaluate the effectiveness of transepithelial cornea impregnation with riboflavin 0.1% by iontophoresis for collagen cross‐linking.Material and methods:  Transepithelial collagen cross‐linking by iontophoresis of riboflavin was performed in a series of 22 eyes of 19 patients with progressive keratoconus I–II of Amsler classification. The riboflavin solution was administered by iontophoresis for 10 min in total, after which standard surface UVA irradiation (370 nm, 3 mW/cm2) was performed at a 5‐cm distance for 30 min.Results:  The riboflavin/UVA treatment resulted in a decrease in the average keratometry level from 46.47 ± 1.03 to 44.12 ± 1.12 D 1 year after the procedure. Corneal astigmatism decreased from 3.44 ± 0.48 to 2.95 ± 0.23 D. Uncorrected distance visual acuity improved from 0.61 ± 0.44 up to 0.48 ± 0.41 (LogMAR). Preoperative and postoperative endothelial cell density remained unchanged at 2765 ± 21.15 cells/mm2.Conclusion:  Transepithelial collagen cross‐linking by iontophoresis might become an effective method for riboflavin impregnation of the corneal stroma reducing the duration of the procedure and being more comfortable for the patients. Further long‐term studies are necessary to complete the evaluation of the efficacy and risk spectrum of the modified cross‐linking technique.

4 April 2016 in Acta Ophthalmologica
Verified
Journal Article
Open access
PDF file
GBGuzel Bikbova
Guzel Bikbova
MBMukharram M. Bikbov
Mukharram M. Bikbov
Purpose: To compare the results of standard corneal crosslinking (CXL) and transepithelial iontophoresis‐assisted CXL after 24 months follow‐up.Material and methods: Corneal crosslinking (CXL) was performed in a series of 149 eyes of 119 patients with keratoconus I–II of Amsler classification. Depending on the CXL method, patients were divided into two groups: (1) 73 eyes with standard CXL and (2) 76 eyes with transepithelial iontophoresis‐assisted CXL. Depending on the group, epithelium removal or administration of riboflavin solution by iontophoresis for 10 min was performed, after which standard surface UVA irradiation (370 nm, 3 mW/cm2) was performed at a 5‐cm distance for 30 min.Results: A statistically significant difference in corrected distance visual acuity (CDVA) was observed between the two groups, with a better outcome in the second group after 6 months (p = 0.037); however, no significant difference was found 24 months after treatment (p = 0.829). Stabilization and regression of keratometry values were achieved in both groups, but standard CXL was more effective. The average demarcation line depth in the standard CXL group was 292 ± 14 μm after 14 days and 172 ± 16 μm in the transepithelial iontophoresis‐assisted CXL group. No demarcation line was detected after 1 month and 3 months in 45% and 100% of the eyes in the second group respectively.Conclusion: Transepithelial iontophoresis‐assisted collagen crosslinking showed to be less effective than standard CXL after 24 months of follow‐up, possibly due to a more superficial formation of corneal collagen crosslinks, however the stopping of disease progression was achieved 24 months after procedure.

2 March 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
MBMukharram M. Bikbov
Mukharram M. Bikbov
TGTimur R. Gilmanshin
Timur R. Gilmanshin
GKGyulli M. Kazakbaeva
Gyulli M. Kazakbaeva
RZRinat M. Zainullin
Rinat M. Zainullin
EREllina M. Rakhimova
Ellina M. Rakhimova
JJJost B. Jonas
Jost B. Jonas
Parallel to the increase in urbanization and associated changes in lifestyle, the prevalence of axial myopia has increased in the past 3 decades, in particular in East and Southeast Asia.1 Because myopia, mainly high myopia, can lead to marked loss in vision due to the sequelae of myopic maculopathy and high myopia–associated optic neuropathy, myopic maculopathy has become one of the most common causes of irreversible vision loss.2-7 Despite the importance of myopic maculopathy in public health, to our knowledge, no information has been available thus far about the prevalence of myopic maculopathy in Russia, Eastern Europe, and Central Asia, although Russia is by area the world´s largest and by population one of the most populous countries.8 It has also remained unclear which systemic factors and major diseases are associated with a higher prevalence of myopic maculopathy. We therefore conducted this population-based study to assess the frequency of myopic maculopathy in an ethnically mixed population in Russia and explore associations between myopic maculopathy and other ocular and systemic parameters.

5 May 2023 in Ophthalmology
Verified
Journal Article
Open access
JVJoëlle E. Vergroesen
Joëlle E. Vergroesen
ASAlexander K. Schuster
Alexander K. Schuster
KSKelsey V. Stuart
Kelsey V. Stuart
NANigus Asefa
Nigus Asefa
ACAudrey Cougnard-Grégoire
Audrey Cougnard-Grégoire
AKAnthony P. Khawaja
Anthony P. Khawaja
To investigate the association of commonly used systemic medications with glaucoma and intraocular pressure (IOP) in the European population. Meta-analysis of eleven population-based cohort studies of the European Eye Epidemiology (E3) consortium. A total of 143240 participants were included in the glaucoma analyses and 47177 participants in the IOP analyses. We examined associations of four categories of systemic medications (antihypertensive medications: beta-blockers, diuretics, calcium channel blockers [CCBs], alpha-agonists, angiotensin-converting-enzyme inhibitors, angiotensin II receptor blockers; lipid-lowering medications; antidepressants; antidiabetic medications) with glaucoma prevalence and IOP. Glaucoma ascertainment and IOP measurement method were according to individual study protocols. Multivariable regression analyses were carried out in each study and results were pooled using random effects meta-analyses. Associations with antidiabetic medications were examined in diabetic participants only. Glaucoma prevalence and IOP. In the meta-analyses of our maximally-adjusted multivariable models, use of CCBs was associated with a higher prevalence of glaucoma (odds ratio [OR] with corresponding 95% confidence interval [95% CI]: 1.23 [1.08 to 1.39]). This association was stronger for monotherapy of CCBs with direct cardiac effects (OR [95% CI]: 1.96 [1.23 to 3.12]). The use of other antihypertensive medications, lipid-lowering medications, antidepressants or antidiabetic medications were not clearly associated with glaucoma. Use of systemic beta-blockers was associated with a lower IOP (Beta [95% CI]: -0.33 [-0.57 to -0.08] mmHg). Monotherapy of both selective (Beta [95% CI]: -0.45 [-0.74 to -0.16] mmHg) and non-selective (Beta [95% CI]: -0.54 [-0.94 to -0.15] mmHg) systemic beta-blockers was associated with lower IOP. There was a suggestive association between use of high-ceiling diuretics and lower IOP (Beta [95% CI]: -0.30 [-0.47; -0.14] mmHg), but not when used as monotherapy. Use of other antihypertensive medications, lipid-lowering medications, antidepressants, or antidiabetic medications were not associated with IOP. We identified a potentially harmful association between use of CCBs and glaucoma prevalence. Additionally, we observed and quantified the association of lower IOP with systemic beta-blocker use. Both findings are potentially important given that glaucoma patients frequently use systemic antihypertensive medications. Determining whether the CCB association is causal should be a research priority.

1 February 2019 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MBMukharram M. Bikbov
Mukharram M. Bikbov
GKGyulli M Kazakbaeva
Gyulli M Kazakbaeva
TGTimur R Gilmanshin
Timur R Gilmanshin
RZRinat M Zainullin
Rinat M Zainullin
IAInga I Arslangareeva
Inga I Arslangareeva
JJJost B. Jonas
Jost B. Jonas
To assess the normal distribution of axial length and its associations in a population of Russia. The population-based Ural Eye and Medical Study included 5,899 (80.5%) individuals out of 7328 eligible individuals aged 40+ years. The participants underwent an ocular and systemic examination. Axial length was measured sonographically (Ultra-compact A/B/P ultrasound system, Quantel Medical, Cournon d'Auvergne, France). Biometric data were available for 5707 (96.7%) individuals with a mean age of 58.8±10.6 years (range:40–94 years; 25%, 50%, 75% quartile: 51.0, 58.0, 66.0 years, respectively). Mean axial length was 23.30±1.10 mm (range: 19.02–32.87mm; 95% confidence interval (CI): 21.36–25.89; 25%, 50%, 75% quartile: 22.65mm, 23.23mm, 23.88mm, resp.). Prevalences of moderate myopia (axial length:24.5-26.5mm) were 555/5707 (8.7%;95%CI:9.0,10.5) and 78/5707 (1.4%;95%CI:1.1,1.7), respectively. Longer axial length (mean:23.30±1.10mm) was associated (correlation coefficient r2:0.70) with older age (P<0.001;standardized regression coefficient beta:0.14), taller body height (P<0.001;beta:0.07), higher level of education (P<0.001;beta:0.04), higher intraocular pressure (P<0.001;beta:0.03), more myopic spherical refractive error (P<0.001;beta:-0.55), lower corneal refractive power (P<0.001;beta:-0.44), deeper anterior chamber depth (P<0.001;beta:0.20), wider anterior chamber angle (P<0.001;beta:0.05), thinner peripapillary retinal nerve fiber layer thickness (P<0.001;beta:-0.04), higher degree of macular fundus tessellation (P<0.001;beta:0.08), lower prevalence of epiretinal membranes (P = 0.01;beta-0.02) and pseudoexfoliation (P = 0.007;beta:-0.02) and higher prevalence of myopic maculopathy (P<0.001;beta:0.08). In that model, prevalence of age-related macular degeneration (any type: P = 0.84; early type: P = 0.46), diabetic retinopathy (P = 0.16), and region of habitation (P = 0.27) were not significantly associated with axial length. Mean axial length in this typically multi-ethnic Russian study population was comparable with values from populations in Singapore and Beijing. In contrast to previous studies, axial length was not significantly related with the prevalences of age-related macular degeneration and diabetic retinopathy or region of habitation.